Biomarkers voor darmkamer bij patiënten met Primair Scleroserende Cholangitis en een inflammatoire darmziekte: de VIP studie
Recruiting
- Conditions
- Primair scleroserende cholangitis, primary sclerosing cholangitis, Inflammatory bowel disease, inflammatoire darmziekte, Ulcerative Colitis, Colitis Ulcerosa.
- Registration Number
- NL-OMON26884
- Lead Sponsor
- Academic Medical Center (AMC), Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Group 1:
- Diagnosis of PSC, established by cholangiography, in whom secondary causes of sclerosing cholangitis have been excluded
Exclusion Criteria
- Medical history of proctocolectomy
- Use of biologic therapy other than vedolizumab within 8 weeks of enrolment
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in expression of previously identified potential biomarkers with regard to copy number changes, cancer-relevant gene mutations, methylation status, as well as MIF expression in patients with PSC/IBD versus IBD, stratified by vedolizumab treatment.
- Secondary Outcome Measures
Name Time Method - Evaluation of potential markers in peripheral blood samples in order to evaluate clinical applicability of the potential markers.<br /><br>- Differences between PSC/IBD and IBD in the identified gene alterations.